- Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infectionAnthony Dimitrov
Profectus BioSciences Inc, Techcenter at UMBC, Room 4011, 1450 South Rolling Road, Baltimore, MD 21227, USA
Curr Opin Investig Drugs 8:653-61. 2007..Ibalizumab had reached phase II clinical trials; however, there are currently no ongoing clinical trials...
- Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infectionYongjun Guan
Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Proc Natl Acad Sci U S A 106:3952-7. 2009..These data suggest that plasma Ab repertoires can underestimate the breadth of humoral immunity, and analyses of B(Mem) should be included in studies correlating Ab specificity with protective immunity to HIV-1...
- Rapamycin Enhanced Efficiency of Anti-HIV AntibodiesAntony Dimitrov; Fiscal Year: 2007..The objective of this Phase I SBIR proposal is to identify potential combinations of rapamycin and antiviral antibodies that may have clinical potential. [unreadable] [unreadable] [unreadable]..
- Rapamycin enhanced efficacy of small-molecule HIV entry inhibitorsAntony Dimitrov; Fiscal Year: 2008..Preclinical and clinical development of such combinations will be the subject of follow-on SBIRs. [unreadable] [unreadable] [unreadable]..